Extended Data Fig. 8: Individual clinical and immune correlative data – Arm C.
From: Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial
a-d. Immune activity against targeted (a) and non-targeted (b) TAAs pre-and postinfusion, tracking (a) and longitudinal functionality assessment (c-d) of circulating unique clones in pt no.53 who remains disease-free after 66 months of follow-up. c. proportion of functional TAA-reactive unique clonotypes. d. multiple effector molecule production as assessed by scRNA-seq. e-j. Immune activity against targeted (e) and non-targeted (f) TAAs pre-and postinfusion, tracking (e) and longitudinal functionality assessment (g-h) of circulating unique clones in pt no.12 who had a prolonged relapse-free period following tumor resection. In addition, tumor expression of PRAME and Survivin and T cell infiltration (with unique mTAA-derived clones representing 0.27% of total tumor T cell content) was confirmed by IHC staining on material excised during surgery following the first infusion* (i). The intratumoral presence of CD3 + T cells (both CD4+ and CD8+) was also demonstrated by flow cytometry (j). k-n. immune activity against targeted (k) and non-targeted (l) TAAs pre-and postinfusion and tracking (k) of circulating unique clones in pt no.54 who remained disease-free long term post-surgery. Moreover, tumor expression of PRAME and Survivin and T cell infiltration (with unique mTAA-derived clones representing 0.13% of total tumor T cell content) was confirmed by IHC staining on material excised during surgery following the first infusion* (m). The intratumoral presence of CD3 + T cells (both CD4+ and CD8+) was also demonstrated by flow cytometry (n). * IHC experiments were performed once on each independent patient sample. Inset scale bars, 50μm.
